Tie 2 Symposium

A World of Indications

For one small molecule, AKB-9778 has a huge potential.

Learn more...

World of Indications

New Approach for IBD

AKB-4924 strengthens the immune system and epithelial cells of the gut in preclinical models.

Learn more...

IBD Pill
(click on a compound for more information)
AKB-9778 AKB-4924

Aerpio Therapeutics is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases.

Learn more...

9/2/14 - Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases

Read the press release.

5/5/14 - Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778

Read the press release.

4/23/14 - Aerpio Therapeutics Closes $22M Financing

Read the press release.